These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29734045)

  • 1. Immune evasion of the CD1d/NKT cell axis.
    Brutkiewicz RR; Yunes-Medina L; Liu J
    Curr Opin Immunol; 2018 Jun; 52():87-92. PubMed ID: 29734045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses.
    Webb TJ; Carey GB; East JE; Sun W; Bollino DR; Kimball AS; Brutkiewicz RR
    Pathog Dis; 2016 Aug; 74(6):. PubMed ID: 27297969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes Simplex Virus 1 Specifically Targets Human CD1d Antigen Presentation To Enhance Its Pathogenicity.
    Rao P; Wen X; Lo JH; Kim S; Li X; Chen S; Feng X; Akbari O; Yuan W
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A VP22-Null HSV-1 Is Impaired in Inhibiting CD1d-Mediated Antigen Presentation.
    Liu J; Gallo RM; Duffy C; Brutkiewicz RR
    Viral Immunol; 2016 Sep; 29(7):409-16. PubMed ID: 27327902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.
    Webb TJ; Giuntoli RL; Rogers O; Schneck J; Oelke M
    Clin Cancer Res; 2008 Dec; 14(23):7652-8. PubMed ID: 19047090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The surveillance of viral infections by the unconventional Type I NKT cell.
    Rajashekar V; Stern L; Almeida CF; Slobedman B; Abendroth A
    Front Immunol; 2024; 15():1472854. PubMed ID: 39355244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role and regulation of CD1d in normal and pathological B cells.
    Chaudhry MS; Karadimitris A
    J Immunol; 2014 Nov; 193(10):4761-8. PubMed ID: 25381357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKT cells: friend or foe during viral infections?
    Diana J; Lehuen A
    Eur J Immunol; 2009 Dec; 39(12):3283-91. PubMed ID: 19830742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKT-cell-based immunotherapies in clinical trials.
    Exley MA; Nakayama T
    Clin Immunol; 2011 Aug; 140(2):117-8. PubMed ID: 21592864
    [No Abstract]   [Full Text] [Related]  

  • 10. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis.
    Hix LM; Shi YH; Brutkiewicz RR; Stein PL; Wang CR; Zhang M
    PLoS One; 2011; 6(6):e20702. PubMed ID: 21695190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Natural Killer T Cells in Solid Malignancies.
    Ingram Z; Madan S; Merchant J; Carter Z; Gordon Z; Carey G; Webb TJ
    Cells; 2021 May; 10(6):. PubMed ID: 34072042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes simplex virus 1 glycoprotein B and US3 collaborate to inhibit CD1d antigen presentation and NKT cell function.
    Rao P; Pham HT; Kulkarni A; Yang Y; Liu X; Knipe DM; Cresswell P; Yuan W
    J Virol; 2011 Aug; 85(16):8093-104. PubMed ID: 21653669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
    Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
    Front Immunol; 2018; 9():1266. PubMed ID: 29928278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.
    Metelitsa LS
    Clin Immunol; 2011 Aug; 140(2):119-29. PubMed ID: 21095162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commensal microbial regulation of natural killer T cells at the frontiers of the mucosal immune system.
    Zeissig S; Blumberg RS
    FEBS Lett; 2014 Nov; 588(22):4188-94. PubMed ID: 24983499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V alpha14 i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes.
    Kinjo Y; Kronenberg M
    J Clin Immunol; 2005 Nov; 25(6):522-33. PubMed ID: 16380816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
    Tiper IV; Webb TJ
    Cancer Immunol Immunother; 2016 Nov; 65(11):1411-1421. PubMed ID: 27614429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From Lysosomal Storage Diseases to NKT Cell Activation and Back.
    Pereira CS; Ribeiro H; Macedo MF
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
    Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
    Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKT-cell glycolipid agonist as adjuvant in synthetic vaccine.
    Liu Z; Guo J
    Carbohydr Res; 2017 Nov; 452():78-90. PubMed ID: 29080431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.